Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; School of Pharmacy, Hainan Provincial Key Laboratory for Research and Development of Tropical Herbs, International Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, Hainan Medical University, Haikou 571199, China.
School of Pharmacy, Hainan Provincial Key Laboratory for Research and Development of Tropical Herbs, International Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, Hainan Medical University, Haikou 571199, China.
Adv Drug Deliv Rev. 2024 Jun;209:115323. doi: 10.1016/j.addr.2024.115323. Epub 2024 Apr 21.
With the aging population on the rise, neurodegenerative disorders have taken center stage as a significant health concern. The blood-brain barrier (BBB) plays an important role to maintain the stability of central nervous system, yet it poses a formidable obstacle to delivering drugs for neurodegenerative disease therapy. Various methods have been devised to confront this challenge, each carrying its own set of limitations. One particularly promising noninvasive approach involves the utilization of focused ultrasound (FUS) combined with contrast agents-microbubbles (MBs) to achieve transient and reversible BBB opening. This review provides a comprehensive exploration of the fundamental mechanisms behind FUS/MBs-mediated BBB opening and spotlights recent breakthroughs in its application for neurodegenerative diseases. Furthermore, it addresses the current challenges and presents future perspectives in this field.
随着人口老龄化的加剧,神经退行性疾病已成为一个重大的健康关注点。血脑屏障(BBB)在维持中枢神经系统稳定性方面发挥着重要作用,但它也给神经退行性疾病治疗药物的输送带来了巨大的障碍。人们设计了各种方法来应对这一挑战,每种方法都有其自身的局限性。一种特别有前途的非侵入性方法是利用聚焦超声(FUS)联合对比剂-微泡(MB)来实现血脑屏障的短暂和可逆开放。本综述全面探讨了 FUS/MB 介导的血脑屏障开放的基本机制,并重点介绍了其在神经退行性疾病应用方面的最新突破。此外,还讨论了该领域目前面临的挑战和未来的展望。
Expert Rev Neurother. 2015-5
ACS Appl Mater Interfaces. 2025-7-2
Front Pharmacol. 2025-3-27
Neurotherapeutics. 2024-9